Literature DB >> 15059189

Parasite-specific antibody and cytokine profiles in newborns from Plasmodium falciparum and Entamoeba histolytica/dispar-infected mothers.

Astrid K Kirch1, Abram Agossou, Meba Banla, Wolfgang H Hoffmann, Hartwig Schulz-Key, Peter T Soboslay.   

Abstract

Passage of parasites and their antigens across the placenta occurs with metazoan as well as protozoan parasites, and this study addressed to which extent exposure to and infection of mothers with Plasmodium spp. and Entamoeba histolytica/dispar has sensitized their offspring for parasite-specific immune responses. While at delivery none of the mothers presented with an acute malaria attack, 42% were seropositive for P. falciparum. In half of the mothers cysts of E. histolytica/dispar were detected in stool specimen, 51% of them were found seropositive for E. histolytica, and E. histolytica-specific immunoglobulin A (IgA) responses were detected in neonates of seropositive mothers as well. Umbilical cord blood cells (UCBC) from neonates, when activated with the mitogen phytohaemagglutinine (PHA) and bacterial streptolysin O (SL-O), released significantly less interferon (IFN)-gamma, interleukin (IL)-10 and tumor necrosis factor (TNF)-alpha into cell culture supernatants than peripheral blood cells (PBMC) of mothers. In response to Plasmodium- and Entamoeba-specific antigens UCBC and PBMC produced equal amounts of IL-1beta, TNF-alpha, IFN-gamma and IL-5, but PBMC from mothers secreted significantly more IL-10. Parasite-specific production of inflammatory and Th(1)- and Th(2)-type cytokines was similar in newborns of Plasmodium and Entamoeba seropositive and seronegative mothers. In summary, repeated exposure and subclinical infection of mothers with E. histolytica or P. falciparum will suffice to prime in utero their children for inflammatory and both Th(1)- and Th(2)-type cytokine responses, and such broad and mixed cytokine spectrum may be of advantage upon secondary parasite challenge in later life.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15059189     DOI: 10.1046/j.1399-3038.2003.00126.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  6 in total

1.  Proinflammatory and regulatory cytokines and chemokines in infants with uncomplicated and severe Plasmodium falciparum malaria.

Authors:  E Ayimba; J Hegewald; A Y Ségbéna; R G Gantin; C J Lechner; A Agosssou; M Banla; P T Soboslay
Journal:  Clin Exp Immunol       Date:  2011-11       Impact factor: 4.330

2.  Distinct Th1- and Th2-Type prenatal cytokine responses to Plasmodium falciparum erythrocyte invasion ligands.

Authors:  Indu Malhotra; Peter Mungai; Eric Muchiri; John Ouma; Shobhona Sharma; James W Kazura; Christopher L King
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  Chemokine levels and parasite- and allergen-specific antibody responses in children and adults with severe or uncomplicated Plasmodium falciparum malaria.

Authors:  B Wangala; A Vovor; R G Gantin; Y F Agbeko; C J Lechner; X Huang; P T Soboslay; C Köhler
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2015-03-26

4.  Effect of praziquantel treatment of Schistosoma mansoni during pregnancy on immune responses to schistosome antigens among the offspring: results of a randomised, placebo-controlled trial.

Authors:  Robert Tweyongyere; Patrice A Mawa; Macklyn Kihembo; Frances M Jones; Emily L Webb; Stephen Cose; David W Dunne; Birgitte J Vennervald; Alison M Elliott
Journal:  BMC Infect Dis       Date:  2011-09-02       Impact factor: 3.090

5.  A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses.

Authors:  Yenny Djuardi; Erliyani Sartono; Heri Wibowo; Taniawati Supali; Maria Yazdanbakhsh
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

6.  IL-10 release by bovine epithelial cells cultured with Trichomonas vaginalis and Tritrichomonas foetus.

Authors:  Ricardo Chaves Vilela; Marlene Benchimol
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-02       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.